DK2884978T3 - Nye Kappa-opioidligander - Google Patents

Nye Kappa-opioidligander Download PDF

Info

Publication number
DK2884978T3
DK2884978T3 DK13829428.5T DK13829428T DK2884978T3 DK 2884978 T3 DK2884978 T3 DK 2884978T3 DK 13829428 T DK13829428 T DK 13829428T DK 2884978 T3 DK2884978 T3 DK 2884978T3
Authority
DK
Denmark
Prior art keywords
kappa opioid
opioid ligand
new kappa
new
ligand
Prior art date
Application number
DK13829428.5T
Other languages
Danish (da)
English (en)
Inventor
Edward Roberts
Miguel A Guerrero
Mariangela Urbano
Hugh Rosen
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK2884978T3 publication Critical patent/DK2884978T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DK13829428.5T 2012-08-16 2013-08-16 Nye Kappa-opioidligander DK2884978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683861P 2012-08-16 2012-08-16
PCT/US2013/055313 WO2014028829A1 (en) 2012-08-16 2013-08-16 Novel kappa opioid ligands

Publications (1)

Publication Number Publication Date
DK2884978T3 true DK2884978T3 (da) 2019-09-30

Family

ID=50101521

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13829428.5T DK2884978T3 (da) 2012-08-16 2013-08-16 Nye Kappa-opioidligander

Country Status (8)

Country Link
US (4) US9682966B2 (enExample)
EP (2) EP3584246A1 (enExample)
JP (3) JP6254163B2 (enExample)
AU (3) AU2013302497A1 (enExample)
CA (1) CA2882132C (enExample)
DK (1) DK2884978T3 (enExample)
ES (1) ES2750640T3 (enExample)
WO (1) WO2014028829A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750640T3 (es) 2012-08-16 2020-03-26 Scripps Research Inst Ligandos opioides kappa novedosos
US10982041B2 (en) * 2016-02-25 2021-04-20 Swancor Advanced Materials Co., Ltd. Epoxy resin oligomer
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
DK3596069T3 (da) * 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019113419A1 (en) * 2017-12-08 2019-06-13 The Rockefeller University Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
KR20250141271A (ko) * 2023-02-17 2025-09-26 더 스크립스 리서치 인스티튜트 카파-오피오이드 수용체 길항제로서 작용하는 퀴놀린 유도체
WO2024216046A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
EP4762046A1 (en) * 2023-08-18 2026-06-24 The Scripps Research Institute Kappa-opioid receptor antagonists
TW202515866A (zh) * 2023-09-05 2025-04-16 大陸商西藏海思科製藥有限公司 Kor拮抗劑及其在醫藥上的應用
WO2025250535A1 (en) 2024-05-28 2025-12-04 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia
WO2025257758A1 (en) 2024-06-11 2025-12-18 Assia Chemical Industries Ltd. Solid state forms of navacaprant
WO2026103730A1 (zh) * 2024-11-15 2026-05-21 江苏恩华药业股份有限公司 一种具有kappa受体拮抗活性的吡啶并芳基的双氮杂环衍生物及其组合物和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014171A1 (de) * 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
JP2525552B2 (ja) 1992-01-23 1996-08-21 東レ株式会社 モルヒナン誘導体および医薬用途
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
ES2325140T3 (es) * 1998-04-20 2009-08-26 ABBOTT GMBH & CO. KG Amidas sustituidas con heterociclos como inhibidores de la calpaina.
US6284769B1 (en) 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
AU2004274403A1 (en) * 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
ES2374629T3 (es) 2004-03-17 2012-02-20 Pfizer Products Incorporated Nuevos derivados de bencil(iden)-lactama.
DE602005023763D1 (de) * 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GB0510204D0 (en) * 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007045462A2 (de) * 2005-10-19 2007-04-26 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
WO2007050348A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
CA2708741A1 (en) 2007-12-10 2009-06-18 Glaxo Group Limited Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011025799A1 (en) * 2009-08-26 2011-03-03 Glaxo Group Limited Cathepsin c inhibitors
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
ES2552932T3 (es) * 2009-12-29 2015-12-03 Suven Life Sciences Limited Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
ES2750640T3 (es) 2012-08-16 2020-03-26 Scripps Research Inst Ligandos opioides kappa novedosos

Also Published As

Publication number Publication date
US20250346584A1 (en) 2025-11-13
JP6254163B2 (ja) 2017-12-27
US20250066336A1 (en) 2025-02-27
JP2015531764A (ja) 2015-11-05
ES2750640T3 (es) 2020-03-26
EP2884978B1 (en) 2019-07-17
WO2014028829A1 (en) 2014-02-20
US20150210673A1 (en) 2015-07-30
JP2020090518A (ja) 2020-06-11
US9682966B2 (en) 2017-06-20
AU2013302497A1 (en) 2015-03-05
EP2884978A4 (en) 2016-01-13
EP2884978A1 (en) 2015-06-24
AU2018201522A1 (en) 2018-03-22
AU2019246921A1 (en) 2019-10-31
JP2018058873A (ja) 2018-04-12
CA2882132C (en) 2021-07-06
EP3584246A1 (en) 2019-12-25
US20180099954A1 (en) 2018-04-12
AU2019246921B2 (en) 2021-04-01
US10118915B2 (en) 2018-11-06
CA2882132A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
DK2776436T3 (da) Nye forbindelser
BR302012005490S1 (pt) Configuracao aplicada a tablet
BR302012005488S1 (pt) Configuracao aplicada a tablet
BR302012005492S1 (pt) Configuracao aplicada a tablet
LT2903991T (lt) Antifibroziniai piridinonai
JP2012236821A5 (ja) 有機金属錯体
DK2684610T4 (da) Bruser
EP2824794A4 (en) Charging cable
DK2755963T3 (da) Nye dihydroquinolin-2-on-derivater
EP2912485A4 (en) POSITIONING
DE102013108016A8 (de) Sicherheitshülle
EP2815053A4 (en) GATE
IL239447A0 (en) Novel compounds
DK2692448T3 (da) Brusehoved
EP2900475A4 (en) Drop detection
CL2012002088S1 (es) Dispensador
DE112012006872T8 (de) Numeriksteuervorrichtung
EP2809729A4 (en) Siloxane polyether copolymers
EP2896338A4 (en) SHOWER UNIT
EP2877291A4 (en) Rotary nozzle
BR302013002456S1 (pt) Dispensador
HUE053273T2 (hu) Opioid készítmények
DK2836494T3 (da) Nye alkyleringsmidler
EP2816324A4 (en) MEASURING DEVICE
DK3106464T3 (da) Nye forbindelser